Insider buying last 90 days
No open-market insider purchases were filed for ADPT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ADPT insider filing, plotted on the chart in Gekko.Open ADPT in Gekko
NASDAQ: ADPT
Adaptive Biotechnologies (ADPT) Stock Analysis & Forecast
Sep 28 close
$28.51−0.92 (−3.1%)
Gekko Brief
Adaptive Biotechnologies closed at $28.51 on 28 September 2026, -3.1% on the day. The price sits above both the 50-day ($25.10) and 200-day ($18.40) moving averages, inside a 52-week range of $12.00 to $29.96. The GekkoIndex reads 45.6, in the Neutral zone, up 3 points over five sessions. Gekko Fair Value is $25.60, so the price is 11.4% above it.
The next earnings report is due on 4 November 2026, 36 days away (after close). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 7.6% across the report. Seasonally, the next 20 trading days from this point averaged +5.8% over the last 5 years, rising in 3 of them.
8 firms rate the stock: 7 buy, 1 hold and 0 sell, with a consensus target of $26.36. A typical daily move is about 4.6%, and a typical 20-day move about 13.1%. On the swing-trade checklist, 3 items read supportive and 1 reads as a headwind (fair value).
Generated Sep 29, 2026 from the data above.
Adaptive Biotechnologies price vs fair value
Close $28.51200-day averageGekko Fair Value $25.60
Adaptive Biotechnologies quick facts
- Market cap
- $4.56B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.40
- Revenue, TTM
- $308.1M
- Profit margin
- -20.7%
- Dividend yield
- —
- Beta
- 2.10
- Volume
- 2.64M avg 2.27M
- 1-year return
- +117.1%
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±13.1%
- 50-day average
- $25.10
- 200-day average
- $18.40
- Next earnings
- Nov 4 after close
- Shares outstanding
- 159.6M
Adaptive Biotechnologies swing-trade checklist
Adaptive Biotechnologies scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $28.51 is above the 50-day ($25.10) and 200-day ($18.40) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
45.6, Neutral
Reading 45.6 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
11.4% above
Price is 11.4% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.8% on average
From this point in the calendar, the next 20 trading days averaged +5.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Adaptive Biotechnologies stock chart and price history
Adaptive Biotechnologies closed at $28.51 on Sep 28, 2026, +117.1% over the past year, inside a 52-week range of $12.00 to $29.96.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +7.8%
- 3 months
- +33.2%
- 6 months
- +129.7%
- 1 year
- +117.1%
The full ADPT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ADPT in Gekko
Follow Adaptive Biotechnologies through every session
Put ADPT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ADPT in GekkoFree for 7 days. No credit card required.
Adaptive Biotechnologies GekkoIndex: the smart money zone
Adaptive Biotechnologies’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.6, in the Neutral zone, up 3 points over five sessions.
45.6Neutral
Up 3 points over five sessions, from the Distribution zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 22 | +5.2% | +12.5% | ||
| Accumulation | 148 | +5.8% | +9.9% | ||
| Neutral (current zone) | 302 | −0.5% | +2.9% | ||
| Distribution | 51 | −1.0% | −2.6% | ||
| Selling | 4 | Too few readings yet | |||
Average ADPT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ADPT price, zone by zone.Track ADPT in Gekko
Is Adaptive Biotechnologies stock overvalued? Gekko Fair Value
Adaptive Biotechnologies trades 11.4% above Gekko Fair Value of $25.60, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Adaptive Biotechnologies shares are worth, recalculated every trading day.
$25.60
Gekko Fair Value, Sep 29, 2026
11.4% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ADPT in Gekko
Adaptive Biotechnologies insider and Congress trading
No open-market insider purchases were filed for Adaptive Biotechnologies, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ADPT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ADPT, plotted on the chart in Gekko.Open ADPT in Gekko
Buybacks
Adaptive Biotechnologies has been buying back its own shares.
- Latest authorization
- $25.00M, Jun 15, 2026
- Bought back, quarter ended Jun 30, 2026
- $25.00M
- As a share of market cap
- 0.55%
From company filings.
Adaptive Biotechnologies earnings: next date and track record
Adaptive Biotechnologies reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- −$0.10
- Revenue estimate
- $71.65M
8 of 8reports beat the EPS estimate
±7.6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | −$0.10 est −$0.13 | $71.55M est $65.44M | +0.1% |
| May 5, 2026 | −$0.13 est −$0.16 | $70.90M est $61.03M | −0.5% |
| Feb 5, 2026 | −$0.09 est −$0.19 | $71.68M est $60.89M | −8.8% |
| Nov 5, 2025 | $0.06 est −$0.14 | $93.97M est $59.38M | −8.0% |
| Aug 5, 2025 | −$0.17 est −$0.24 | $58.88M est $55.40M | +7.1% |
| May 1, 2025 | −$0.20 est −$0.28 | $52.44M est $42.13M | +33.7% |
| Feb 11, 2025 | −$0.23 est −$0.24 | $47.46M est $46.05M | −1.7% |
| Nov 7, 2024 | −$0.22 est −$0.27 | $46.44M est $40.21M | +1.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Adaptive Biotechnologies stock forecast and analyst price targets
Analysts’ average 12-month price target for Adaptive Biotechnologies is $26.36, −7.5% from the last close, from 8 firms rating the stock in the last 90 days.
$26.36consensus 12-month target, −7.5% from the last close
Now $28.51Avg $26.36
Low $22High $34
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 22 | BTIG | $34 | +19.3% |
| Sep 17 | Craig-Hallum | — | — |
| Aug 24 | Piper Sandler | $27.50 | −3.5% |
| Aug 4 | Piper Sandler | $27.50 | −3.5% |
| Jul 30 | Piper Sandler | $20 | −29.8% |
+2.9%average 20-day move after past Neutral readings
+5.8%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Adaptive Biotechnologies seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Adaptive Biotechnologies averaged +5.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +6.5% | 3 of 5 |
| Next 10 trading days | +4.4% | 3 of 5 |
| Next 15 trading days | +3.4% | 3 of 5 |
| Next 20 trading days | +5.8% | 3 of 5 |
| Next 30 trading days | +12.1% | 4 of 5 |
For scale, ADPT’s typical 20-trading-day move in either direction is about 13.1%.
Adaptive Biotechnologies market cap and key statistics
Adaptive Biotechnologies’s market cap is $4.56B and revenue of $308.1M over the last twelve months.
Valuation
- Market cap
- $4.56B
- EPS, TTM
- −$0.40
- Gekko Fair Value
- $25.60
Trading
- Volume
- 2.64M
- Avg volume, 20 days
- 2.27M
- 52-week high
- $29.96
- 52-week low
- $12.00
- Shares outstanding
- 159.6M
Financials
- Revenue, TTM
- $308.1M
- Profit margin
- -20.7%
- Return on equity
- -38.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.10
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±13.1%
Adaptive Biotechnologies stock news this week
Coverage of Adaptive Biotechnologies this week reads positive: 3 positive, 3 neutral and 1 negative headlines.
- Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.comInvesting.com Canada, Sep 28
- Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock By Investing.comInvesting.com Canada, Sep 28
- Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of CureGlobeNewsWire, Sep 25
- Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 4.4% - Should You Buy?MarketBeat, Sep 24
- Adaptive Biotechnologies stock hits 52-week high at 28.79 USDInvesting.com, Sep 24
- Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT)Defense World, Sep 24
Adaptive Biotechnologies peers
Adaptive Biotechnologies’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Adaptive Biotechnologies stock FAQ
What is Adaptive Biotechnologies’s market cap?
Adaptive Biotechnologies’s market cap is $4.56B at the Sep 28, 2026 close of $28.51, with 159.6M shares outstanding.
What is the Adaptive Biotechnologies stock forecast?
The consensus analyst 12-month price target for Adaptive Biotechnologies is $26.36, −7.5% from the last close. Of the 8 firms that rated the stock in the last 90 days, 7 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Adaptive Biotechnologies stock overvalued or undervalued?
On Gekko’s estimate Adaptive Biotechnologies is overvalued: the Sep 28, 2026 close of $28.51 is 11.4% above Gekko Fair Value of $25.60. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Adaptive Biotechnologies report earnings next?
Adaptive Biotechnologies is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of −$0.10 per share on revenue of $71.65M. Adaptive Biotechnologies beat the earnings estimate in 8 of its last 8 reports, moving 7.6% on average across the report.
What is Adaptive Biotechnologies’s 52-week high and low?
Adaptive Biotechnologies’s 52-week high is $29.96 and its 52-week low is $12.00; it closed at $28.51 on Sep 28, 2026, +117.1% over the past year. Over the last five years the shares peaked at $37.55 on Nov 8, 2021.
Is Adaptive Biotechnologies stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Adaptive Biotechnologies the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.